lucatumumab
atezolizumab
patritumab
-umab
agonistic monoclonal antibody
intrabody
antigenomic
alloantibody
cibisatamab
reagin
teplizumab
dorlixizumab
immunonaive
robatumumab
zolimomab
biciromab
panitumumab
siltuximab
sulesomab
chromobody
conatumumab
antiantibody
olendalizumab
monoclonal
presentation
-a-
drozitumab
-ab
pancytokeratin
idiospecific
oleclumab
Forssman antibody
iratumumab
heterophil antibody
onartuzumab
heterophile antibody
polyantibody
properdin
polyvalent
dacetuzumab
complement
antiustekinumab
Ab
bezlotoxumab
brentuximab
-i-
immunoprobe
sifalimumab
lenzilumab
polytypic